Ningetinib Tosylate

对甲苯磺酸宁格替尼

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameNingetinib Tosylate
Drug Alias Name宁格替尼CT-053-PTSACT-053
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsMacrophage-stimulating protein receptor inhibitorsAXL receptor tyrosine kinase inhibitors +[5] 
TargetsVascular endothelial growth factor receptor 2Macrophage-stimulating protein receptorTyrosine-protein kinase receptor FLT3 +[5] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHec Pharm Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSunshine Lake Pharma Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursLung NeoplasmsStomach Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A